First-in-Class ADC Ups Survival in mTNBC First-in-Class ADC Ups Survival in mTNBC

For patients with metastatic triple-negative breast cancer for whom several therapies failed, progression-free and overall survival almost doubled with the novel antibody-drug conjugate, trial data indicate.Medscape Medical News
Source: Medscape General Surgery Headlines - Category: Surgery Tags: Hematology-Oncology News Source Type: news